Suchergebnisse
10
Alles
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
04. März 2025 08:10 ET
|
Alzamend Neuro, Inc.
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder at Massachusetts General Hospital
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
02. Oktober 2024 16:05 ET
|
Processa Pharmaceuticals, Inc.
Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap’s safety-efficacy profile and help to define...
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting
27. August 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio and SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat...
MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights Analysis 2024: Focus on 10 ML1 Inhibitor Drug In Clinical Trials, Insight By Company, Indication and Phase
26. August 2024 11:02 ET
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights 2024" report has been added to ResearchAndMarkets.com's offering. ...
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
30. Juli 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA)...
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
01. Februar 2024 07:30 ET
|
BioRestorative Therapies, Inc
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at...
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
08. September 2023 08:30 ET
|
BioRestorative Therapies, Inc
--Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— --15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE,...
AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant
18. August 2023 10:37 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., Aug. 18, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the commencement...
First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
13. Juli 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
05. Juli 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...